NCT05160168 - A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions

Gastrointestinal Stromal Tumors (GIST)Neoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmDigestive System DiseaseGastrointestinal Diseases

Interventions

DRUG

THE-630

Oral THE-630 administered once daily in a continuous regimen

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

32224

Mayo Clinic Florida, Jacksonville

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

85258

HonorHealth Research Institute, Scottsdale

97239

Oregon Health & Science University, Portland

02215

Dana Farber Cancer Institute, Boston